VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces that it intends to change its corporate name from “Algernon Health Inc.” to “Grey Matters Health Inc.” (the “Name Change”). The Company has reserved the new name and new symbol “GREY” with the Canadian Securities Exchange (the “CSE”). The new symbols for the OTCQB and Frankfurt exchange will be provided shortl ...

Core Viewpoint - Algernon Pharmaceuticals Inc. has officially changed its name to Algernon Health Inc., effective October 20, 2025, reflecting its new focus on the Alzheimer's Disease diagnostic market [1][4]. Group 1: Name Change Details - The company's common shares will trade under the new name on the Canadian Securities Exchange (CSE) with a new CUSIP number (01559C106) and ISIN (CA01559C1068), while the stock symbol remains unchanged [2][1]. - The name change will be reflected across the company's website, digital marketing, social media, and email addresses over a short period [3]. Group 2: Business Focus and Initiatives - The name change aligns with the company's strategy to establish specialized neuroimaging clinics across North America, utilizing advanced Positron Emission Tomography (PET) scanning technology to detect amyloid plaques in Alzheimer's patients [4]. - The PET scanning systems will provide significantly lower radiation exposure compared to standard PET/CT machines and are covered by Medicare, Medicaid, and private insurance [4]. Group 3: Equipment and Financing Agreements - The company has signed a definitive equipment order and financing agreement with Catalyst MedTech for four Oncovision CareMiBrain™ PET scanner systems, valued at over CDN $4 million, to be used in the planned neuroimaging clinics [5]. - An additional agreement is in place to acquire six more systems for future clinic establishments on an adjusted cost basis [5]. Group 4: Leadership and Vision - The CEO of Algernon Health, Christopher J. Moreau, emphasized that the name change is a significant step in executing the new healthcare initiative aimed at early-stage detection of Alzheimer's disease [6]. - The company continues to operate a private subsidiary, Algernon NeuroScience, which is advancing a psychedelic program for stroke and traumatic brain injury recovery, and holds a 20% equity position in Seyltx, a drug development company [6][8].